摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-溴-3-硝基水杨酰苯胺 | 29378-97-0

中文名称
2-溴-3-硝基水杨酰苯胺
中文别名
——
英文名称
2'-Bromo-3-nitrosalicylanilide
英文别名
N-(2-bromophenyl)-2-hydroxy-3-nitrobenzamide
2-溴-3-硝基水杨酰苯胺化学式
CAS
29378-97-0
化学式
C13H9BrN2O4
mdl
——
分子量
337.12
InChiKey
JXBWRDYVZDBUIU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    20
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    95.2
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • ANTIBACTERIAL USE OF HALOGENATED SALICYLANILIDES
    申请人:AntibioTx A/S
    公开号:EP3338783A1
    公开(公告)日:2018-06-27
    The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Gram positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
    本发明涉及一种卤代水杨酰苯胺,选自 closantel、rafoxanide、oxyclozanide 和 niclosamide 及其衍生物,包括盐类、水合物、酯类等,用于局部治疗或预防革兰氏阳性菌如葡萄球菌(尤其是金黄色葡萄球菌)和链球菌(尤其是化脓性链球菌)引起的感染。与常用的局部抗生素相比,使用卤代水杨酰苯胺处理的革兰氏阳性细菌出现耐药性突变体的频率非常低。
  • Halogenated salicylanilides for treating clostridium infections
    申请人:UNION therapeutics A/S
    公开号:US10463680B2
    公开(公告)日:2019-11-05
    The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhea and C. difficile associated colitis.
    本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯,用于治疗梭状芽孢杆菌引起的受试者感染,特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病,包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。
  • Antibacterial use of halogenated salicylanilides
    申请人:UNION therapeutics A/S
    公开号:US10758553B2
    公开(公告)日:2020-09-01
    The invention relates to a halogenated salicylanilide selected from closantel, rafoxanide, oxyclozanide and niclosamide and derivatives thereof including salts, hydrates, esters and the like for use in the topical treatment or prevention of infections caused by Gram-positive bacteria such as Staphylococcus, in particular Staphylococcus aureus, and Streptococcus, in particular Streptococcus pyogenes. Grain positive bacteria treated with the halogenated salicylanilides exhibit a very low frequency of appearance of resistant mutants compared to commonly used topical antibiotics.
    本发明涉及一种卤代水杨酰苯胺,选自closingantel、rafoxanide、oxyclozanide和niclosamide及其衍生物,包括盐类、水合物、酯类等,用于局部治疗或预防革兰氏阳性菌如葡萄球菌,特别是金黄色葡萄球菌和链球菌,特别是化脓性链球菌引起的感染。与常用的局部抗生素相比,使用卤代水杨酰苯胺处理的革兰氏阳性细菌出现抗药性突变体的频率非常低。
  • Halogenated salicylanilides for treating Clostridium infections
    申请人:UNION therapeutics A/S
    公开号:US10857164B2
    公开(公告)日:2020-12-08
    The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by Clostridium bacteria, particularly a C. difficile infection. The halogenated salicylanilides are expected to be useful in the treatment of C. difficile associated diseases including C. difficile associated diarrhoea and C. difficile associated colitis.
    本发明涉及卤代水杨酰苯胺或其药学上可接受的盐或酯,用于治疗梭状芽孢杆菌引起的受试者感染,特别是艰难梭菌感染。卤代水杨酰苯胺有望用于治疗艰难梭菌相关疾病,包括艰难梭菌相关腹泻和艰难梭菌相关结肠炎。
  • Compositions and methods for protecting a host from enteric toxigenic pathogens
    申请人:The Hospital For Sick Children
    公开号:US11166926B2
    公开(公告)日:2021-11-09
    A method of protecting a host from an enteric toxigenic pathogen comprises administering a salicylanilide to the host. A method of reducing virulence of an enteric toxigenic pathogen comprises administering a salicylanilide to a host infected with or at risk of infection with pathogen. A method of reducing recurrence of an infection caused by an enteric toxigenic pathogen, comprises administering a salicylanilide to a host previously infected with the pathogen.
    一种保护宿主免受肠毒性病原体感染的方法包括向宿主施用水杨酰苯胺。一种降低肠道毒性病原体毒力的方法,包括向感染或有可能感染病原体的宿主施用水杨酰苯胺。一种减少由肠道致毒病原体引起的感染复发的方法,包括向先前感染病原体的宿主施用水杨酰苯胺。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐